U.S., June 12 -- ClinicalTrials.gov registry received information related to the study (NCT07641179) titled 'A Study to Evaluate MAR002 for Acromegaly' on May 26.
Brief Summary: Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in participants with acromegaly
Study Start Date: July, 2026
Study Type: INTERVENTIONAL
Condition:
Acromegaly
Intervention:
DRUG: MAR002
Subcutaneous injection
DRUG: Placebo
Subcutaneous injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Marea Therapeutics
Published by HT Digital Content Services with permission from Health Daily Digest....